Pfizer Inc Earnings - Q3 2026 Analysis & Highlights
Pfizer’s Q3 2026 call focused on stronger non-COVID sales and raised full-year guidance, while discussing cost savings, capital allocation, upcoming patent expiries, policy and pricing pressures, and a broad late-stage pipeline.
Key financial results
Revenue was $16.6 billion in Q3, with 7% operational growth in non-COVID products, partly offset by lower COVID-19 product revenue; the call did not state the total revenue year-over-year growth rate.
Adjusted diluted EPS was $0.87, above the company’s expectation and inclusive of a $0.10 Innovent-related charge; reported diluted EPS was $0.56.
Adjusted gross margin was 77%, primarily reflecting favorable product mix and continued cost management; no year-over-year comparison was provided.
Adjusted operating margin was 36%, reflecting cost management and strong non-COVID revenue, as well as higher business investment and the Innovent R&D charge; no year-over-year comparison was provided.
Adjusted operating expenses were $6.8 billion; adjusted R&D expense increased 18% operationally, while acquired in-process R&D decreased 52% operationally.
Operating cash flow was $8.8 billion year to date through Q3, and quarter-end leverage was 2.6 times.
Business segment results
The call did not provide revenue or profit by formal business segment; it reported results by product and product group.
Launched and acquired products generated $3.8 billion in Q3 revenue and grew 32% operationally; growth was led by Padcev, up $255 million, Nurtec, up $135 million, and Lorbrena, up $114 million.
The acquired-product portfolio grew 37% operationally; Pfizer cited strong performance from its legacy Seagen portfolio, which grew 39% year over year in the U.S., driven by Padcev.
Nurtec grew 33% operationally, supported by underlying demand and commercial execution.
Pfizer reported solid Q3 contributions from Eliquis, Padcev, the Vyndaqel family, Nurtec, and Lorbrena, while COVID-19 products and the Prevnar family declined.
Capital allocation
Pfizer’s stated priorities are to reinvest in the business at appropriate returns, maintain and over time grow the dividend, and preserve financial flexibility for value-enhancing actions, including potential share repurchases.
In the first nine months of 2026, Pfizer invested $9.2 billion in internal and external R&D and returned $7.3 billion to shareholders through its quarterly dividend.
After the Innovent transaction, Pfizer estimated its current business-development capacity at approximately $6 billion.
Management said the company expects to maintain its dividend through the LOE period; share repurchases may again become a tool for shareholder returns after that period.
Pfizer expects leverage to remain around current levels or modestly higher during the patent-expiry transition.
Industry trends and dynamics
Management described obesity treatment as a market with distinct patient profiles and purchasing channels, including patients seeking aesthetic-driven weight management and patients seeking greater efficacy and tolerability.
Pfizer said its China launch experience reinforced its view that success in chronic weight management requires a product portfolio and access to multiple channels.
In China, Pfizer said type 2 diabetes approval for ecnoglutide would open additional hospital and e-commerce channels, and it was awaiting a final reimbursement review after passing the NRDL committees.
Management noted that oral CGRP medicines compete in a competitive market, while saying Pfizer leads the oral CGRP class in the U.S. and is working to extend that position internationally.
Pfizer said infection rates and treatment demand will continue to influence Paxlovid utilization.
Competitive landscape
Pfizer positioned atirmociclib as a potential next-generation option for HR-positive breast cancer, designed for greater CDK4 selectivity and reduced CDK6 engagement; management cited 33 times greater selectivity for CDK4 than CDK6.
In a Phase 2 study, atirmociclib plus fulvestrant reduced the risk of disease progression or death by 40% versus investigator’s choice; Pfizer noted the study population had previously received a CDK4/6 inhibitor.
Pfizer said cross-trial comparisons of atirmociclib safety with approved CDK4/6 inhibitors have limitations, while citing numerically lower Grade 3 or higher neutropenia and fewer dose reductions in the reported data.
For tilrekimig in atopic dermatitis, Pfizer said Phase 2 results suggested potential superiority to dupilumab, but acknowledged cross-trial comparison limitations; its Phase 3 program includes a head-to-head study.
Pfizer reported that tivunatamig’s confirmed response rate in its ongoing Phase 2 lung cancer study was approximately 80%, with median progression-free survival of nearly 14 months for both histologies; management cautioned that comparisons with other therapies were cross-trial and limited.
Pfizer characterized Padcev-plus-pembrolizumab as a relevant comparator in muscle-invasive bladder cancer and said the VOLGA data did not yet establish which patients could receive less therapy in a curative-intent setting.
Macroeconomic environment
Management said it expected no MFN policy changes, viewing the agreements as signed and in effect through the current government’s term; it also said it did not expect broader policy changes, while noting that policy remained under close monitoring.
Pfizer identified IRA-related MFP pricing, 340B impacts and changes, and MFN effects as factors to incorporate into its 2027 guidance.
Management said its 2025 concerns about potential tariff and MFN effects had eased after the company navigated those issues, which it said had restored investor confidence in the sector.
Pfizer cited upcoming patent expiries as a material business pressure, including U.S. expiries for Ibrance and Xtandi and international Eliquis LOE at the end of 2026.
Growth opportunities and strategies
Pfizer said its launched and acquired products, together with its commercial execution, are intended to help offset LOE headwinds and support a return to growth toward the end of the decade.
The company plans 10 active and planned Phase 3 obesity trials in 2026, including a study evaluating a switch from approved weekly therapies to investigational monthly GLP-1 berobenatide; it is working toward a potential first approval for berobenatide in 2028.
Pfizer said the SOLIS-1 Phase 2b study of amylin alone and amylin plus berobenatide was fully recruited, with an efficacy readout expected in the second half of 2027.
Pfizer described Elrexfio’s positive Phase 3 results as supporting development in earlier lines of multiple myeloma; its eligible patient population could grow approximately five-fold, subject to clinical and regulatory success.
Pfizer is advancing tilrekimig in atopic dermatitis, severe asthma, and COPD; management expected readouts in 2028 and 2029 for the asthma and COPD programs.
Pfizer said its next-generation pneumococcal vaccine candidates are designed for broad serotype and invasive-disease coverage; it estimated PCV25 could protect against serotypes causing 84% of invasive disease cases in U.S. children under five, an approximately 25-percentage-point increase versus Prevnar 20.
Management said it is using AI to improve manufacturing efficiency, physician and patient engagement, R&D target validation and molecule and biomarker selection; it also cited the GENESIS pharmacovigilance platform as an example of AI and automation in safety monitoring.
Pfizer said it is prioritizing bolt-on acquisitions that complement its portfolio and therapeutic-area expertise, rather than making a large acquisition its primary focus.
Financial Guidance and Outlook
Pfizer raised full-year 2026 revenue guidance by $1.5 billion at the midpoint to $62.0 billion–$64.0 billion.
The company reaffirmed expected COVID product revenue of approximately $4 billion, with most Comirnaty revenue expected in Q4.
Pfizer raised and narrowed full-year adjusted diluted EPS guidance to $2.95–$3.05, an increase of $0.10 at the midpoint while absorbing the $0.10-per-share Innovent impact.
Full-year 2026 R&D expense is now expected to be $10.8 billion–$11.8 billion; Pfizer reaffirmed the other components of its financial guidance.
The company expects full-year adjusted gross margin in the mid-70% range and said its updated outlook reflects confidence in non-COVID products, cost-improvement progress, and continued priority-pipeline investment.
Pfizer expects to deliver nearly all of the anticipated $7.2 billion in net savings by the end of 2026 and has initiated a further program targeting $2.5 billion in net savings from 2027 through 2029.
Management said the additional savings are expected to help mitigate margin erosion during the 2027–2029 LOE transition.
Pfizer said it would provide 2027 guidance around mid-December; cited drivers include LOEs, growth in launched and acquired products, pricing effects including MFN and IRA, and cost initiatives.
Pfizer reiterated a line of sight to risk-adjusted high-single-digit revenue CAGR from year-end 2028 through year-end 2033, supported by growth in newer and acquired products and pipeline opportunities across multiple therapeutic areas.
